Get started
CHINA RESOURCES PHARMACEUTICAL GRCHINA RESOURCES PHARMACEUTICAL GRCHINA RESOURCES PHARMACEUTICAL GR

CHINA RESOURCES PHARMACEUTICAL GR

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

3320 chart


Full chart

3320 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪34.81 B‬HKD
Dividend yield (indicated)
4.70%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪4.26 B‬HKD
Revenue (FY)
‪270.40 B‬HKD
Shares float
‪1.82 B‬
Beta (1Y)
1.05

Employees


Employees (FY)
‪72.99 K‬
Change (1Y)
‪+5.99 K‬ +8.93%
Revenue / Employee (1Y)
‪474.32 K‬HKD
Net income / Employee (1Y)
‪7.47 K‬HKD

About CHINA RESOURCES PHARMACEUTICAL GR


Sector
Health Technology
Headquarters
Hong Kong
Founded
1938
Website
crpharm.com
ISIN
HK0000311099
FIGI
BBG00DZWSDQ5
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. It operates through the following segments: Manufacturing, Distribution, Retail, and Others. The Manufacturing segment handles the research and development, manufacture, and sale of pharmaceutical and healthcare products. The Distribution segment focuses on the distribution, warehousing, logistics, and pharmaceutical supply chain solutions and services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. The Retail segment deals with the operation of retailing of pharmacy stores. The Others segment comprises of property holding. The company was founded in 1938 and is headquartered in Hong Kong.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

3320 news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 3320 is 5.73 HKD — it has increased by 1.44% in the past 24 hours. Watch CHINA RESOURCES PHARMACEUTICAL GR stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange CHINA RESOURCES PHARMACEUTICAL GR stocks are traded under the ticker 3320.
3320 stock has fallen by −3.60% compared to the previous week, the month change is a −8.62% fall, over the last year CHINA RESOURCES PHARMACEUTICAL GR has showed a 16.46% increase.
We've gathered analysts' opinions on CHINA RESOURCES PHARMACEUTICAL GR future price: according to them, 3320 price has a max estimate of 9.88 HKD and a min estimate of 5.86 HKD. Watch 3320 chart and read a more detailed CHINA RESOURCES PHARMACEUTICAL GR stock forecast: see what analysts think of CHINA RESOURCES PHARMACEUTICAL GR and suggest that you do with its stocks.
3320 reached its all-time high on Sep 5, 2018 with the price of 13.16 HKD, and its all-time low was 3.18 HKD and was reached on Dec 20, 2021. View more price dynamics on 3320 chart.
See other stocks reaching their highest and lowest prices.
3320 stock is 2.87% volatile and has beta coefficient of 1.05. Track CHINA RESOURCES PHARMACEUTICAL GR stock price on the chart and check out the list of the most volatile stocks — is CHINA RESOURCES PHARMACEUTICAL GR there?
Today CHINA RESOURCES PHARMACEUTICAL GR has the market capitalization of ‪34.81 B‬, it has decreased by −2.96% over the last week.
Yes, you can track CHINA RESOURCES PHARMACEUTICAL GR financials in yearly and quarterly reports right on TradingView.
CHINA RESOURCES PHARMACEUTICAL GR is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
3320 earnings for the last half-year are 0.44 HKD per share, whereas the estimation was 0.46 HKD, resulting in a −4.33% surprise. The estimated earnings for the next half-year are 0.24 HKD per share. See more details about CHINA RESOURCES PHARMACEUTICAL GR earnings.
CHINA RESOURCES PHARMACEUTICAL GR revenue for the last half-year amounts to ‪138.17 B‬ HKD, despite the estimated figure of ‪138.62 B‬ HKD. In the next half-year revenue is expected to reach ‪138.48 B‬ HKD.
3320 net income for the last half-year is ‪2.82 B‬ HKD, while the previous report showed ‪3.04 B‬ HKD of net income which accounts for −7.09% change. Track more CHINA RESOURCES PHARMACEUTICAL GR financial stats to get the full picture.
CHINA RESOURCES PHARMACEUTICAL GR dividend yield was 3.31% in 2023, and payout ratio reached 25.03%. The year before the numbers were 2.53% and 24.24% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 5, 2024, the company has ‪72.99 K‬ employees. See our rating of the largest employees — is CHINA RESOURCES PHARMACEUTICAL GR on this list?
Like other stocks, 3320 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CHINA RESOURCES PHARMACEUTICAL GR stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CHINA RESOURCES PHARMACEUTICAL GR technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CHINA RESOURCES PHARMACEUTICAL GR stock shows the buy signal. See more of CHINA RESOURCES PHARMACEUTICAL GR technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.